Sensus Healthcare, Inc. (SRTS)
| Market Cap | 50.54M -1.1% |
| Revenue (ttm) | 17.51M -53.4% |
| Net Income | -15.49M |
| EPS | -0.94 |
| Shares Out | 16.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,965 |
| Open | 3.040 |
| Previous Close | 3.050 |
| Day's Range | 3.030 - 3.095 |
| 52-Week Range | 2.660 - 5.490 |
| Beta | 1.14 |
| Analysts | Strong Buy |
| Price Target | 5.38 (+75.24%) |
| Earnings Date | Nov 5, 2026 |
About SRTS
Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 V... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for SRTS stock is "Strong Buy." The 12-month stock price target is $5.38, which is an increase of 75.24% from the latest price.
News
Sensus Healthcare price target lowered to $5.50 from $6.50 at Alliance Global
Alliance Global analyst Scott Henry lowered the firm’s price target on Sensus Healthcare (SRTS) to $5.50 from $6.50 and keeps a Buy rating on the shares. Sensus Healthcare’s Q2 results…
Sensus Healthcare reports Q2 EPS (53c), consensus (11c)
Reports Q2 revenue $2.3M, consensus $4.6M. “While our reported second quarter revenue was impacted by the timing of financing approvals for eight units, our commercial execution remained strong throug...
Sensus Healthcare price target lowered to $4 from $4.50 at Lake Street
Lake Street analyst Ben Haynor lowered the firm’s price target on Sensus Healthcare (SRTS) to $4 from $4.50 and keeps a Buy rating on the shares following Q2, which the…
Sensus Healthcare Earnings Call Transcript: Q2 2026
Q2 2026 revenue fell sharply year-over-year due to delayed recognition of 8 units, but commercial momentum and pipeline strength improved. Management expects a stronger second half, with sequential unit growth and increased recurring revenue from software and Fair Deal Agreements.
Sensus Healthcare Earnings release: Q2 2026
Sensus Healthcare released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Sensus Healthcare Quarterly report: Q2 2026
Sensus Healthcare has published its Q2 2026 quarterly earnings report on August 13, 2026.
Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological...
Sensus Healthcare to Report Second Quarter 2026 Financial Results and Hold Business Update Conference Call on August 13, 2026
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological...
Sensus Healthcare management to meet virtually with Lake Street
Virtual Meeting to be held on June 18 hosted by Lake Street.
Sensus Healthcare management to meet virtually with Lake Street
Virtual Meeting to be held on May 21 hosted by Lake Street.
Sensus Healthcare Announces Amicable Resolution of Commercial Dispute with SkinCure Oncology
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, tod...
Sensus Healthcare price target lowered to $6.50 from $7.50 at Alliance Global
Alliance Global lowered the firm’s price target on Sensus Healthcare (SRTS) to $6.50 from $7.50 and keeps a Buy rating on the shares, citing lower forecasts following the company’s Q1…
Sensus Healthcare reports Q1 EPS (16c), consensus (11c)
Reports Q1 revenue $3.4M, consensus $5.32M. “During the first quarter, we began our efforts in educating and training our existing customer base as well as our many new prospects. We…
Sensus Healthcare Earnings Call Transcript: Q1 2026
Revenue declined year-over-year due to loss of a major customer, but underlying growth was seen from a diversified base. New CPT codes and software initiatives are driving increased adoption, recurring revenue, and a positive outlook for sequential quarterly improvement in 2026.
Sensus Healthcare Earnings release: Q1 2026
Sensus Healthcare released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Sensus Healthcare Quarterly report: Q1 2026
Sensus Healthcare has published its Q1 2026 quarterly earnings report on May 7, 2026.
Sensus Healthcare Reports First Quarter 2026 Financial Results and Business Highlights
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological...
Sensus Healthcare Proxy statement: Proxy filing
Sensus Healthcare filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Sensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological...
Sensus Healthcare files lawsuit against SkinCure for breach of contract
Sensus Healthcare (SRTS) announced the filing of a lawsuit in the Circuit Court for the Fifteenth Judicial Circuit in and for Palm Beach County, Florida, against SkinCure Oncology alleging breach…
Sensus Healthcare Files Lawsuit Against SkinCure Oncology for Breach of Contract
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for...
Sensus Healthcare initiated with a Buy at Alliance Global
Alliance Global analyst Scott Henry initiated coverage of Sensus Healthcare (SRTS) with a Buy rating and $7.50 price target Sensus sells the SRT-100/Vision medical device to deliver superficial radiat...
Sensus Healthcare Introduces Sensus Link, Brings Advanced Operating Capabilities to the SRT-100™ Installed Base
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for...
Sensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for...
Sensus Healthcare price target lowered to $6 from $8 at Maxim
Maxim analyst Anthony Vendetti lowered the firm’s price target on Sensus Healthcare (SRTS) to $6 from $8 and keeps a Buy rating on the shares. The company’s Q4 results were…